Pacific 8 Ventures

Pacific 8 Ventures is a venture capital firm that specializes in investments in transformative technologies, particularly within the healthcare sector. The firm focuses on a range of innovative fields, including healthcare technology, information technology, robotics, artificial intelligence, machine learning, 3D printing, insurance technology, and blockchain. By targeting these sectors, Pacific 8 Ventures aims to support and accelerate the development of groundbreaking solutions that can significantly impact healthcare and related industries.

Ser-Chen Fu

Partner

Jack Liang

Founding Partner and Executive

16 past transactions

BillionToOne

Series C in 2022
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

Fauna Bio

Seed Round in 2021
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bio leverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases.

BillionToOne

Series A in 2020
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

hi.health

Seed Round in 2020
hi.health offers people with private health insurance convenient and safe access to health care billing via app or web. Users can easily submit their invoices digitally and hi.health takes care of the further processing, billing and customer service providing a seamless user experience. With the integrated “library” users receive a transparent overview of relevant digital health products and services, that are (partially) covered by their insurance. hi.health operates at the intersection of digital health, fintech and insurtech. While each of these rapidly growing markets are already exciting in themselves, their combination in one product is unique. The company was founded by Sebastian Gruber and Fredrik Debong in July 2019. Since hi.health launched in Germany at the end of 2019 several thousand users already use the independent billing app.

Mammoth Biosciences

Series B in 2020
Mammoth Biosciences, Inc. is a biotechnology company based in South San Francisco, California, founded in 2017. It specializes in developing advanced CRISPR solutions, including its proprietary DETECTR technology, which allows for the detection of specific nucleic acids in samples, aiding in diagnostics for various conditions such as bacterial infections, cancer, and viral infections. The company focuses on democratizing disease detection through accessible point-of-care tests that can simultaneously identify multiple health issues. Additionally, Mammoth offers CRISPR-Cas systems for genome editing, targeting therapeutic applications in immuno-oncology, autoimmune diseases, and liver diseases. Its innovative solutions are utilized across diverse sectors, including healthcare, agriculture, environmental monitoring, and biodefense. Co-founded by CRISPR pioneer Jennifer Doudna, Mammoth Biosciences is supported by notable institutional and individual investors, reflecting its commitment to harnessing CRISPR technology for significant advancements in life sciences.

Fauna Bio

Seed Round in 2019
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bio leverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases.

Fauna Bio

Seed Round in 2019
Fauna Bio is developing new ways to treat human diseases, such as heart disease and neurodegenerative disease, by adopting mechanisms animals have developed for traits such as hibernation and deep-diving. Founded by three scientists who have intimate knowledge of the best science and resources from the field of non-model organisms, Fauna Bio leverages data from hundreds of species in order to help develop pre-clinical and early clinical testing for new therapeutics targeting human diseases.

Hint Health

Series A in 2018
Hint Health Inc. develops a membership management platform for direct care providers. Its platform comprises tools that streamline membership administration and billing for providers and their patient, employer, and health plan clients. The company's offers plans such as essentials, plus, pro, and enterprise. The company was incorporated in 2013 and is headquartered in San Francisco, California.

BillionToOne

Seed Round in 2017
BillionToOne Inc. develops a genetic testing platform that detects and measures disease at the molecular level. It offers UNITY, a noninvasive prenatal screening that tests fetal cell-free DNA for cystic fibrosis and spinal muscular atrophy through a single sample of the mother's blood. The company serves doctors and expecting mothers. BillionToOne Inc. was incorporated in 2016 and is based in Menlo Park, California.

Karius

Series A in 2017
Karius, Inc. is a life sciences company dedicated to generating genomic insights for infectious diseases. It offers the Karius Test, a non-invasive blood test that utilizes sequencing of microbial cell-free DNA to identify and quantify various pathogens, including bacteria, DNA viruses, fungi, and parasites. This test is particularly useful for diagnosing complicated pneumonia, infections in immunocompromised patients, and endocarditis. Karius also provides laboratory services for pathogen biomarker detection tailored for biopharmaceutical companies. Founded in 2014, the company is based in Redwood City, California, with an additional office in Menlo Park. Its laboratory holds CLIA certification and CAP accreditation, allowing it to conduct high-complexity clinical laboratory testing to support rapid clinical decision-making.

Multiply Labs

Venture Round in 2017
Multiply Labs specializes in the manufacturing of personalized pharmaceutical capsules tailored to the specific needs of individual patients. By integrating pharmaceutical science with advanced robotics technology, the company has developed a unique robotic manufacturing facility that allows for the production of these capsules efficiently and cost-effectively. Multiply Labs is notable for being the first company to successfully introduce 3D printed capsules to the market, enabling the pharmaceutical industry to deliver medications that align with the unique metabolic requirements of patients.

Wellthie

Series A in 2017
Wellthie Inc., an insurance technology company, offers broker and carrier shopping tools to simplify insurance distribution for small businesses and individuals. It offers cloud-based e-commerce platform for selling tools, medical and ancillary quotes, broker management dashboard, modeling and scenario planning, online storefront, custom client proposals, distribution channels, marketplace product promotion, small group and individual analysis, market insights, and consumer engagement. The company was founded in 2013 and is headquartered in New York, New York.

Quantified Care

Seed Round in 2016
Quantified Care (QC) is a dveloper of a multimedia software platform for chronic care and post-discharge management with tools for patients and clinical management teams. Patients on the platform receive personalized updates and feedback based on symptoms, medication, and vitals data collected through regular check-ins delivered through the patient’s preferred mode of communication (mobile app, Alexa, text, phone call, or web portal). Data is captured manually or passively from connected devices and wearables. While patients receive support, clinical teams have access to analytics stratifying patients into high, medium, and low risk tiers based on QC’s clinical intelligence engine. Alerts trigger key clinical resources to take action while a secure communication layer facilitates remote patient engagement.

Labdoor

Series A in 2016
Labdoor, Inc. is a company based in South San Francisco, California, that specializes in the online sale of dietary supplements and energy drinks. The product range includes fish oils, herbal supplements, magnesium, melatonin, probiotics, protein, and zinc supplements. Labdoor operates as a testing laboratory that verifies the quality of consumer products, particularly supplements. Through its website, Labdoor.com, consumers can access scientific reviews of products and shop for those that have undergone rigorous testing for purity and potency. The company offers a "Labdoor Certified" program for manufacturers who submit their products for quality control testing, ensuring that consumers receive reliable information about what they are purchasing. Labdoor publishes detailed reports and grades on various products, enabling consumers to make informed decisions about their health and supplement needs.

Cohero Health

Series A in 2016
Cohero Health, Inc. is a digital respiratory health company that focuses on improving the management of asthma and chronic obstructive pulmonary disease (COPD). Founded in 2012 and based in New York, the company offers a proprietary connected health platform that combines sensor-based technology with a mobile application. This platform includes the BreatheSmart app, which provides customized medication reminders, records inhaler usage, and tracks lung function, symptoms, and environmental conditions over time. Cohero Health's product suite features mSpirometer lung function sensors and HeroTracker, a Bluetooth-enabled inhaler tracker that monitors both control and rescue medications. Additionally, BreatheSmart Connect serves as a Software-as-a-Service solution for remote patient monitoring and communication, enhancing coordination between patients and healthcare providers. By utilizing these tools, Cohero Health aims to improve medication adherence and overall health outcomes for individuals with respiratory conditions.

Hint Health

Seed Round in 2016
Hint Health Inc. develops a membership management platform for direct care providers. Its platform comprises tools that streamline membership administration and billing for providers and their patient, employer, and health plan clients. The company's offers plans such as essentials, plus, pro, and enterprise. The company was incorporated in 2013 and is headquartered in San Francisco, California.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.